Rafagen Overview
- Founded
- 2007
- Status
- Out of Business
- Latest Deal Type
- Out of Business
Rafagen General Information
Description
Developer of next generation gene expression systems designed to solve problems in molecular therapeutics. The company's gene expression systems are developed with genetically engineered CHO cells and also provides services like gene cloning, codon optimization, gene synthesis, cell culture scale up, cell based assays and fow cytometry, enabling physicians to kill cancer cells with the highest possible efficiencies while leaving normal cells unharmed.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
- 9700 Great Seneca Highway
- Suite 191
- Rockville, MD 20850
- United States
+1 (301) 000-0000
Rafagen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Out of Business | 01-Aug-2016 | 00000 | Completed | Out of Business | ||
| 4. Grant | 04-Nov-2010 | 00000 | Completed | Startup | ||
| 3. Corporate | 16-Dec-2009 | 00000 | Completed | Startup | ||
| 2. Early Stage VC | 01-Apr-2009 | $237K | Completed | Startup | ||
| 1. Accelerator/Incubator | 09-Jul-2008 | $237K | $237K | Completed | Startup |
Rafagen Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Sung Hahm Ph.D | Co-Founder, President & Chief Executive Officer | ||
| Ja Koo Ph.D | Co-Founder & Chief Technology Officer |